Indian Institute of Toxicology Research (Council of Scientific and Industrial Research), Lucknow-226 001, India.
Expert Rev Proteomics. 2010 Feb;7(1):127-39. doi: 10.1586/epr.09.91.
Proteomic technologies are widely used to understand the molecular mechanism of Parkinson's disease (PD) and to develop biomarkers for its early diagnosis. The differential expression patterns of brain, cerebrospinal fluid and blood proteins of patients or chemically induced animal models are used to identify protein fingerprints for developing diagnostic and therapeutic strategies for PD. A number of differentially expressed proteins associated with energy metabolism, oxidative stress, signal transduction, electron transport and detoxification pathways are identified using proteomic strategies. Proteomics immensely contributed to the detection of qualitative and quantitative changes of expressed proteins and their post-translational modifications. An update on proteomics-driven research for developing early biomarkers and understanding the molecular aspects of PD, along with their translational snags, challenges and future possibilities, are discussed in this review.
蛋白质组学技术广泛用于了解帕金森病 (PD) 的分子机制，并开发用于其早期诊断的生物标志物。使用患者或化学诱导的动物模型的大脑、脑脊液和血液蛋白质的差异表达模式来鉴定用于开发 PD 的诊断和治疗策略的蛋白质指纹。使用蛋白质组学策略鉴定了与能量代谢、氧化应激、信号转导、电子传递和解毒途径相关的许多差异表达蛋白。蛋白质组学极大地促进了表达蛋白及其翻译后修饰的定性和定量变化的检测。本文综述了蛋白质组学驱动的研究进展，讨论了开发早期生物标志物和了解 PD 的分子方面及其转化障碍、挑战和未来可能性。
